Trimebutine -SIL NDSRI
References
FAQ's
References
- Torossian, Dieran R.; Aubard, Gilbert G., Preparation of esters of amino alcohols, GB1342547A, Jan 3, 1974, Jouveinal S. A. (https://patents.google.com/patent/GB1342547A/en)
- Joo, Eun-Hee; Chang, Woo-Ik; Oh, Injoon; Shin, Sang-Chul; Na, Han-Kwang; Lee, Yong-Bok, High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 723, Issue: 1 + 2, Pages: 239-246, 1999 DOI: (10.1016/s0378-4347(98)00516-7)
Frequently Asked Questions
Why is it necessary to eliminate nitrosamine impurities in drugs?
Nitrosamine impurities have the potential to cause cancer. And so, it is necessary to eliminate nitrosamine impurities in drugs.
Which analytical methods identify Trimebutine impurities?
Reversed-phase High-performance liquid chromatography (RP-HPLC) helps identify Trimebutine impurities.
Why isolation and identification of Trimebutine impurities is essential during drug development?
The presence of Trimebutine impurities in drugs can lengthen the drug process, impact shelf life, and cause unknown health risks to patients.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.